News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TechniScan Medical Systems Teams with Researchers at Moores Cancer Center in Clinical Study With Warm Bath Ultrasound(TM) System


3/9/2010 8:28:02 AM

SALT LAKE CITY, March 9 /PRNewswire-FirstCall/ -- TechniScan, Inc. ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has commenced phase two of its grant study at the University of California, San Diego (UCSD) Moores Cancer Center.

The Moores UCSD Cancer Center is a National Cancer Institute (NCI) designated comprehensive cancer center with scientists and clinicians focused on developing the next generation of cancer therapies and cures. The TechniScan Warm Bath Ultrasound(TM) system investigations will be conducted with Michael P. Andre, Ph.D., Professor of Radiology, and breast radiologists Dr. Linda Olson and Dr. Haydee Ojeda-Fournier.

"We are excited to begin this new phase in the development of WBU(TM); it marks a genuine milestone in which our work may be translated to the front lines of the clinical world, " said Andre.

"Our vision is to begin to create a database of thousands of breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "With complete anonymity, women may contribute their mammograms, breast MRI's and WBU(TM) images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan's imaging network will also allow timely and efficient collaboration of patient's records for her medical team's use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

TechniScan, Inc.






Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES